May 11, 2016

Recruiting the next generation

oicr-careers

Recruiting the next generation of researchers with in-demand skills is essential to the success of a research institute like OICR. On May 6, representatives from OICR attended the University of Toronto Life Sciences Career Development Society’s (LSCDS) Career Day. The Institute’s booth was very busy as students in chemistry, biology, medicine and other fields came by to find out about the research being done at OICR and how their skills could be applied. OICR also held a well-attended ‘Spotlight Session’ to inform students about the Institute’s research programs and the benefits of working at OICR.

Recruiting the next generation of researchers with in-demand skills is essential to the success of a research institute like OICR.

Students were invited to visit OICR later this month to get a firsthand look at the Institute’s facilities, to hear more about current projects and to speak to its researchers about career paths. OICR would like to congratulate LSCDS for a very successful event and thanks to everyone who stopped by to find out more about OICR.

May 1, 2016

Dr. Gang Zheng named to AIMBE College of Fellows for nanotechnology research

Gang-ZhengThe American Institute for Medical and Biological Engineering (AIMBE) elected Dr. Gang Zheng to its College of Fellows for “outstanding contributions on activatable photosensitizers for photodynamic therapy and discovery of porphysome nanotechnology in cancer imaging and therapy.”

Joining the College of Fellows puts Zheng among some elite company.

Zheng is Professor, Leslie Dan Faculty of Pharmacy, and Department of Medical Biophysics, University of Toronto, Senior Scientist, Princess Margaret Cancer Centre, and Core Lead, Techna Institute for the Advancement of Technology for Health (Techna), University Health Network.

Continue reading – Dr. Gang Zheng named to AIMBE College of Fellows for nanotechnology research

May 1, 2016

OICR invests in early-stage Ontario oncology drug development

OICR is supporting new early stage drug discovery research in Ontario, with a $1.2 million investment from OICR’s Drug Discovery Program into five promising oncology research projects selected through a province-wide call for proposals.

This was a new approach to selecting projects for the Drug Discovery team’s research pipeline and one that aligns well with the strategic direction of the team and the Institute, says Dr. Rima Al-awar, Director of OICR’s Drug Discovery Program.

“Traditionally we have relied on several means to generate interest from the community, including informal outreach to other institutions and word of mouth says Al-awar. She points to the recent success of BCL6, a drug target that OICR’s Drug Discovery team developed from early stage research by Dr. Gil Privé at University Health Network. Collaborating with Privé, the team brought the BCL6 project to the point where it attracted major investment from industry.

Continue reading – OICR invests in early-stage Ontario oncology drug development

April 29, 2016

Technology developed with OICR funding receives $4 million in support from NCI

Pathcore slide and logoIn 2006 Dr. Martin Yaffe’s lab at Sunnybrook Research Institute developed a new way of preparing whole-mount sections of breast tissue, which opened up the exciting possibility of correlating pathology directly with medical imaging. However, the huge images that were produced posed a significant challenge to researchers; existing software for viewing images was either incapable of handling the large multi-scale images or it was too expensive and inflexible. To address these issues, Dr. Anne Martel, currently Chief Scientific Officer and co-founder of Pathcore, developed a new technology with funding assistance from OICR.

Continue reading – Technology developed with OICR funding receives $4 million in support from NCI

January 7, 2016

Ontario Institute for Cancer Research invests $1.2 million to support oncology drug development in Ontario

Five promising early stage research projects that would benefit from OICR’s input and expertise were selected from a province-wide call for proposals.

Toronto (January 7, 2016) – Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) announced today that OICR will invest $1.2 million in funding, plus expertise and in-kind support, to help bring five promising oncology drug development projects closer to the clinic.

Continue reading – Ontario Institute for Cancer Research invests $1.2 million to support oncology drug development in Ontario

« Previous Page